Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Ex-PRESS glaucoma minishunt implantation in patient with uncontrolled secondary glaucoma due to ocular ischemic syndrome (OIS): a case report

Poster Details

First Author: W.Kokot POLAND

Co Author(s):    M. Konkol                    

Abstract Details


The purpose of the study is to evaluate the safety and efficacy in lowering intraocular pressure with the EX-PRESS Glaucoma Filtration Device, P-50 Version, placed under a partial-thickness scleral flap with MMC in 65 y.o. female patient with secondary glaucoma due to the Ocular Ischemic Syndrome (OIS) a severe life- and vision-threatening condition.


65 years old female patient was reffered to the hospital because of high values of intraocular pressure in her right eye without response to topical and general medications.


A patient underwent EX-PRESS, P-50 Version implantation under a partial- thickness scleral flap with Mitomycin C. On admission the following investigations were obtained: detailed medical and ocular histories, complete ophthalmic examination, endothelial cell density evaluation, internal carotid artery assesment by duplex ultrasonography, visual field and OCT testing, management and follow-up. Postoperative intraocular pressure readings and complications were recorded.


A patient was diagnosed with secondary glaucoma. The intraocular pressure was decreased from initial IOP of 40 mmHg to 8 mmHg after surgery and 10 mmHg at the last follow-up visit without medications. Early postoperative complications included: shallow AC and a slight hemorrhage in AC which resolved spontaneously. Success rate: At the last follow-up visit patient had an IOP of 10 mmHg.


The EX-PRESS Glaucoma Filtration Device is safe and effective with few complications even when used in the high-risk patient with secondary glaucoma.

Financial Disclosure:


Back to Poster listing